Eximo Medical, an Israel-based developer of transluminal solutions for interventional vascular and gastrointestinal procedures, completed a $1.6M Series A funding round.
The round was led by Accelmed, with participation from the Alfred Mann Institute at the Technion (AMIT), the Technion R&D Foundation Ltd. and a private investor.
Founded in 2012 by Dr. Irit Yaniv, Chairperson, Eximo has developed a patented hybrid catheter, Cathi™, which is connected to a pulsed laser system that operates at 355nm UV. The catheter’s tip combines laser ablation capabilities with a mechanical blunt blade to potentially improve accuracy, and enable precision when passing through a vessel blockage, regardless of the type of lesion or size of the vessel.
The performance of the system and its catheters in treating PAD (the underlying cause of around 66% of limb amputations) will soon be tested in human studies in Europe and Israel during Q4, this year.
The company’s product pipeline includes solutions for Lead Extraction (LE) – the removal of defunct, malfunctioning or infected pacemaker or fibrillator leads and, at a later stage, catheters for interventional gastrointestinal procedures.